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Abstract 
Purpose: To synthesize thiosemicarbazide and determine its antimicrobial properties.  
Methods: Pyridine-based thiosemicarbazide was synthesized, characterized and evaluated for 
antimicrobial activity. The structure of the synthesized compound was established by spectral analysis, 
namely, Fourier transform infrared spectroscopy (FT-IR), proton nuclear magnetic resonance 
spectroscopy (1H NMR), carbon 13 magnetic resonance spectroscopy (13C NMR), liquid 
chromatography-mass spectroscopy (LC-MS), single crystal x-ray analysis as well as by elemental 
analysis.  
Results: The title compound crystallized in monoclinic form with space group P21/c of a = 11.6050 (3) Å, 
b = 13.3130 (4) Å, c = 9.9884 (3) Å, β = 94.911 (2)°, V = 1537.52 (8) Å3, Z = 4 and Rint = 0.033. The 
pyridine ring formed dihedral angles of 74.1(3) and 88.2(5)° with major and minor components of 
disordered benzene ring, respectively. In the crystal packing, molecules were linked via intermolecular 
N—H•••N, N—H•••S and N—H•••O hydrogen bonds into zigzag layers. Compound 2 was most effective 
against Bacillus subtilis ATCC 10400, MRSA 85N, MRSA 66N and MRSA 15G, compared to the 
reference drugs, ampicillin and ceftriaxone.  
Conclusion: The title compound represents a good lead for the development of potent antibacterial 
agent against Gram positive bacteria and MRSA strains. 
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Thiosemicarbazide (NH2-NH-CSNH2) is the 
simplest hydrazine derivative of thiocarbamic 
acid. The chemical behavior of thiosemi-
carbazide is similar to its analogue 
semicarbazide, because of the versatility of 
thione group as compared to keto group, and is 
responsible for diversified behavior of 
thiosemicarbazide. The chemistry of thiosemi-
carbazide and its derivatives is interesting 
because of their synthetic, analytical applications 
and biological activities [1]. 
 
Thiosemicarbazides and their derivatives display 
interesting biological activities, including 
antibacterial [2-6], antifungal [7,8], antimalarial 
[9,10], anti-trypanosomal [11,12], anti-
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mycobacterial [13], anticancer [14], anti-HIV [15], 
anticonvulsant [16,17] and topoisomerase 
inhibition activity [18,19]. The titled compound, N-
(4-chlorophenyl)-2-(pyridin-4-ylcarbonyl) hydra-
zinecarbothioamide, has been reported as the 
most potent anti-Candida agent against Candida 
albicans ATCC 66027, Candida spp. 12810 
(blood) and Candida spp.178 (HVS) with MIC 
value of 0.09 - 0.78 µg/mL, compared with 
standard Iitraconazole, which exhibits the 
inhibitory activity with MIC value of 0.04-1.56 
µg/mL [20]. Solubility studies of the titled 
compound have also been previously reported by 
our group [21-24]. 
 
In the light of previous research and in 
continuation of our interest in the synthesis of 
compounds containing thiosemicarbazide [25-
27], herein, we report the synthesis, 
characterization, single crystal X-ray analysis 
and antimicrobial activity of the title compound, a 






All the solvents were obtained from Merck. The 
homogeneity of the compounds was checked by 
TLC performed on Silica gel G coated plates 
(Merck). Iodine chamber was used for 
visualization of TLC spots. The FT-IR spectra 
were recorded in KBr pellets on a (Spectrum BX) 
Perkin Elmer FT-IR spectrophotometer. Melting 
points were determined on a Gallenkamp melting 
point apparatus, and thermometer was 
uncorrected. NMR Spectra were scanned in 
DMSO-d6 on a Bruker NMR spectrophotometer 
operating at 500 MHz for 1H and 125.76 MHz for 
13C at the Research Center, College of 
Pharmacy, King Saud University, Saudi Arabia. 
Chemical shifts δ are expressed in parts per 
million (ppm) relative to TMS as an internal 
standard and D2O was added to confirm the 
exchangeable protons. Coupling constants (J) 
are in hertz. The following abbreviations are used 
in the assignment of NMR signals: s (singlet), d 
(doublet), m (multiplet).  
 
The mass spectrum was measured on an Agilent 
Triple Quadrupole 6410 TQ LC/MS equipped 
with ESI (electrospray ionization) source. X-ray 
data were collected on a Bruker APEX-II CCD 
diffractometer equipped with graphite 
monochromatic CuKߙ radiation (1.54178 = ߣ) at 
296 K. Cell refinement and data reduction were 
done by Bruker SAINT whereas program used to 
solve structure and refine structure is SHELXS-
97. The elemental analysis for C, H, N and S 
were within the limit of ± 0.4 and ± 0.3 % of the 
theoretical values respectively. 
 
The title compound, N-(4-chlorophenyl)-2-
(pyridin-4-ylcarbonyl) hydrazinecarbothioamide 
(2), was prepared by the reaction of pyridine-4-
carbohydrazide (isoniazid) with p-chlorophenyl 





To a solution of pyridine-4-carbohydrazide 
(isoniazid) 1 (0.01 mmol) in absolute ethanol 
(99.8 %, 25 mL), p-chlorophenyl isothiocyanate 
(0.01 mmol) was added. The mixture was 
refluxed for 2 h and left to cool. The mixture was 
poured into cold water and solid product was 
filtered off, washed with water and petroleum 
ether. The product was dried and finally 





Single crystals were obtained by slow 
evaporation from absolute ethanol. A good 
crystal with dimensions of 0.44 mm x 0.32 mm x 
0.14 mm was selected for X-ray diffraction 
analysis. The final refinement was performed by 
full-matrix least-squares techniques with 
anisotropic thermal data for non-hydrogen atoms 
on 2ܨ. The N-bound and C-bound hydrogen 
atoms were located in difference Fourier maps 
(N–H = 0.77(3) - 0.99(5) Å) and positioned 
geometrically (C–H = 0.93 Å), respectively. Multi-
scan absorption correction was applied by the 
use of SADABS software. The chlorobenzene 
ring is statistically disordered over two 
conformations with a site-occupancy ratio of 
0.654(6): 0.346(6). Similarity (SAME), similar-
ADP (SIMU) and FLAT restraints were used for 
the major and minor components of the 
disordered chlorobenzene ring (Cl1/C1–C6). The 
highest peak is located at 0.88 Å from atom C2, 
whereas the deepest hole is located at 0.52 Å 




Microorganisms: Standard bacterial cultures 
were obtained from American Type Culture 
Collection (ATCC)/National Collection of type 
Culture (NCTC) while the methicillin resistant 
Staphylococcus aureus (MRSA) and extended 
spectrum beta lactamase E. coli (ESBL) culture 
were obtained from Microbiology Unit, 
Department of Pharmaceutics, College of 
Pharmacy, King Saud University, Riyadh, Saudi 
Arabia. The drug resistant strains were 
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characterized by phenotypic testing. All strains 
were maintained on Mueller Hinton Agar during 
the experiment.  
 
The tested compounds were dissolved in Muller 
Hinton Broth with 10 µl/mL DMSO as co-solvent. 
The concentrations ranging from 500 - 0.976 
µg/mL were prepared in 96-well plates with serial 
dilutions. The control without tested compound 
was also used to compare antimicrobial efficacy. 
The organisms were grown in 5 mL Muller Hinton 
broth overnight at 37 oC. The overnight growth 
culture of microorganisms were checked with 0.5 
McFarland standards and diluted to match this 
turbidity standard. Fifty (50) µL of diluted 
bacterial culture was added to each well of tested 
compound. The turbidity was recorded and 
compared with control. IC50 was determined with 
standard method of plotting straight line equation 
on obtained values. Two drugs, i.e., ceftriaxone 
and ampicillin were used as standard drug in the 
experiment. 
 
The MIC of the above drugs was determined 
through commercial MIC E-test strips for 
antimicrobial susceptibility testing (AB Biodisc, 
Dalvagen, SOLNA, Sweden). The 0.5 McFerland 
standard matched bacterial culture was spread 
on Mueller Hinton Agar plate and e test strips 
were placed on it. The lowest concentration of 
drug inhibiting growth of bacteria on culture plate 
was determined as MIC [30]. All experiments 




The synthesis of isoniazid (INH) derivatives was 
carried out as shown in (Scheme 1). 
 
Isoniazid was reacted with p-chlorophenyl 
isothiocyanate in the presence of absolute 
ethanol to yield (2).  The purity of the compound 
was checked by elemental analysis and thin 
layer chromatography (TLC). The compound was 
identified by spectral data. Analytical and 
spectral data of the synthesized compounds 
were in good agreement with composition of the 
synthesized compounds. X-ray analysis reveals 
that compound 2 crystallizes in monoclinic 
system with space group P21/c with a = 11.6050 
(3) Å, b = 13.3130 (4) Å, c = 9.9884 (3) Å, β = 
94.911 (2)° and V = 1537.52 (8) Å3 (Table 1). 
Yield: 70 %; M.p. 210-212 °C; IR (KBr) cm-1: 
3414 (NH str.), 1663 (C=O str.), 1395 (C=S str.); 
1H NMR (DMSO-d6, 500 MHz) δ 7.3-7.4 (4H, m, 
Ar-H), 7.8 (2H, d, J = 5.0 Hz), 8.7 (2H, d, J = 4.5 
Hz),  9.9 (bs, 2H, NH, D2O exchange), 10.8  (s, 
1H, CONH, D2O exchange.). 13C NMR (DMSO-
d6, 125 MHz) δ 206.0, 150.1, 128.5, 127.9, 
121.6; MS (ESI) m/z 306.99 [M]+, 308.03 [M+1]+. 
Analysis: for C13H11N4OSCl (306.77), calcd. C 
50.90,  H 3.61, N 18.26, S 10.45 %; found C 
50.75, H 3.60, N 18.30, S 10.43 %. 
 
The selected geometric parameters and 
hydrogen-bond geometry are shown in Table 2 
and Table 3, respectively. 
 
In the screening for antimicrobial activity for 
compound 2, the compound was evaluated 
against twelve strains of Gram positive, bacteria 
Gram negative bacteria and methicillin resistant 
Staphylococcus aureus (MRSA) (Table 4). 
Compound 2 was effective against Gram-positive 
bacteria and most promising against Bacillus 
subtilis ATCC 10400. Compound 2 was also 
effective against methicillin-resistant 
Staphylococcus aureus (MRSA); MRSA 85N, 
MRSA 66N and MRSA 15G, compared to the 
reference drugs, ampicillin and ceftriaxone. 
MRSA 85N was the most susceptible to 
compound 2. Compound 2 was ineffective 




The 1H NMR (DMSO-d6, 500 MHz) of compound 
2 revealed the singlet signal for NHC=O at δ 10.8 
in addition to broad singlet of NH protons which 
appeared at δ 9.9.The four aromatic protons of 
pyridine ring appeared as two doublets at δ 8.7 
(J = 4.5 Hz) and δ 7.8 (J = 5.0 Hz). The other 
four protons of chlorophenyl ring appeared at δ 
7.3-7.4 as multiplet. The 13C NMR (DMSO-d6, 
125 MHz) of compound 2 exhibited the signal of 
C=S at δ 206.40, while the signal of C=O 
appeared at δ 150.19. The aromatic carbons 
appear at δ 128.55-121-63. The MS (ESI) of 
compound 2 reveals a peak at m/z 306.99 equal 


















Scheme 1: Synthetic pathway of compound 2. Reagents and conditions: (a) Absolute EtOH, reflux 2 h 
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Table 1: Crystal data and structure refinement for compound 2 
 
Crystal data 
Chemical formula C13H11ClN4OS 
Mr 306.77 
Crystal system, space group Monoclinic, P21/c 
Temperature (K) 296 
a, b, c (Å) 11.6050 (3), 13.3130 (4), 9.9884 (3) 
β (°) 94.911 (2) 
V (Å3) 1537.52 (8) 
Z 4 
Radiation type Cu Kα 
µ (mm−1) 3.48 
Crystal size (mm) 0.44 × 0.32 × 0.14 
Data collection 
Diffractometer Bruker APEX-II CCD  
diffractometer 
Absorption correction Multi-scan  
SADABS Bruker 2014 
Tmin, Tmax 0.81, 0.87 
No. of measured, independent and observed [I > 2σ(I)] 
reflections 
10937, 2938, 2537  
Rint 0.033 
Refinement 
R[F2 > 2σ(F2)], wR(F2), S 0.068, 0.211, 1.09 
No. of reflections 2938 
No. of parameters 249 
No. of restraints 175 
Δρmax, Δρmin (e Å−3) 0.65, −0.42 
 
Table 2: Selected geometric parameters (Å, °) 
 
Cl1—C3 1.722 (10) N2—N3 1.388 (3) 
Cl1X—C3X 1.727 (17) N2—C7 1.342 (4) 
S1—C7 1.680 (3) N3—C8 1.337 (3) 
O1—C8 1.209 (3) N4—C12 1.315 (4) 
N1—C7 1.341 (4) N4—C11 1.316 (5) 
N1—C6 1.421 (4)   
C6—N1—C7 126.8 (2) N1—C6—C5 121.2 (4) 
N3—N2—C7 122.3 (2) N1—C6—C1 116.5 (4) 
N2—N3—C8 119.6 (2) S1—C7—N1 125.6 (3) 
C11—N4—C12 117.1 (3) N1—C7—N2 116.9 (2) 
Cl1—C3—C2 119.7 (9) S1—C7—N2 117.6 (2) 
Cl1—C3—C4 120.1 (7) O1—C8—C9 122.1 (2) 
Cl1X—C3X—C4X 122.1 (14) O1—C8—N3 122.2 (2) 
Cl1X—C3X—C2X 118.8 (13) N3—C8—C9 115.69 (19) 
N1—C6—C1X 119.0 (7) N4—C11—C10 123.7 (3) 
N1—C6—C5X 134.2 (6) N4—C12—C13 124.0 (3) 
 
 
Table 3: Hydrogen-bond geometry (Å, °) 
 
D—H···A D—H H···A D···A D—H···A 
N3—H1N1···O1i 0.77 (3) 2.08 (3) 2.786 (3) 152 (3) 
N1—H1N3···N4ii 0.99 (5) 2.05 (5) 3.013 (3) 163 (4) 
N2—H1N2···S1iii 0.81 (4) 2.51 (4) 3.299 (2) 166 (3) 
Symmetry codes: (i) x, −y+3/2, z+1/2; (ii) −x+2, −y+1, −z+1; (iii) −x+2, −y+2, −z+1 
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Table 4: Antimicrobial activity of compound 2 against tested microorganisms 
 
S/no. Microorganisms #MIC50 
(µg/mL) 
MIC (µg/mL) determined through 
E test strips (AB Biodisc)* 
TX AM 
1 MRSA 216P 577.19 >32 >256 
2 MRSA 66N 256.5 >32 >256 
3 MRSA 85N 286.59 >32 >256 
4 MRSA 15G 210.14 >32 >256 
5 Salmonella  typhi ATCC 13311 1089.96 >32 >256 
6 Escherichia coli ATCC 35218 -- >32 >256 
7 Escherichia coli ESBL 6969.73 >32 >256 
8 Bacillus subtilis ATCC 10400 290.43 >32 >256 
9 Shigella sonii ATCC 11060 1469.36 >32 6 
10 Proteus vulgaris ATCC 6380 5653.4 >32 >256 
11 Staphylococcus aureus ATCC 6538 514.57 >32 1.5 
12 Staphylococcus aureus ATCC 6571 2372.64 >32 4 
*TX = ceftriaxone; AM = ampicillin; #Actual MIC of the compound was difficult to determine due to solubility issue, 
so 50 % reduction with minimal concentration of compound against tested microorganism was determined All 
experiments were performed in triplicate 
 
In the compound 2 (Figure. 1), the 
chlorobenzene ring is disordered over two 
positions with a dihedral angle of 64.2(6)° and 
refined site-occupancies of 0.654(6) : 0.346(6). 
The pyridine ring (N4/C9-C13) forms dihedral 
angles of 74.1(3)° and 88.2(5)° with the major 
and minor components of the disordered 
benzene ring (C1-C6) respectively, indicating the 
pyridine ring and benzene ring of the major 
component are almost perpendicular to each 
other. 
 
In the crystal packing, molecules are connected 
to each other, in a zigzag fashion to form sheets 
(Fig. 2a) and these sheets are stacked along the 
a axis (Fig. 2b). Molecules are linked via 
intermolecular N1—H1N3•••N4 and N2—
H1N2•••S1 hydrogen bonds (Table 2) (into 
chains propagating in [010]) together with 
intermolecular N3—H1N1•••O1 hydrogen bonds 
(Table 2), resulting in the formation of zigzag 
layers lying parallel to (100) (Fig. 2b). The 
existence of π•••π interactions involving the 
centroid of the N4/C9-C13 pyridine ring (π•••π 
distance = 3.5108(18) Å) further stabilize the 
molecular packing. The structure of compound 2 
was confirmed using spectral data and x-ray 
single crystal analysis (crystallographic data for 
the structure 2 has been deposited with the 
Cambridge Crystallographic Data Center (CCDC) 




The title compound 2 has been prepared 
efficiently by the reaction of pyridine-4-
carbohydrazide (isoniazid) with p-chlorophenyl 
isothiocyanate in absolute ethanol under reflux 
for 2 h and fully characterized by spectral 
analysis. The 3D structure of the synthesized 
compound 2 was confirmed by the single crystal 
X-ray analysis. Compound 2 is more effective 
against Gram-positive Bacillus subtilis ATCC 
10400 and methicillin-resistant Staphylococcus 
aureus strains, viz, MRSA 85N, MRSA 66N and 
MRSA 15G, than the reference drugs, ampicillin 
and ceftriaxone. Finally, the titled compound 
represents a good lead for the development of 
newer and potent antibacterial agent against 
Gram-positive and MRSA strains. 
 
 
Figure 1: ORTEP diagram of compound 2 with thermal ellipsoids at 40 % probability showing phenyl ring 
disorder 
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Figure 2: Crystal packing of compound 2, viewed along (a) a and b axes and (b) c axis. H atoms not involved in 
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